See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.
Type 2 Diabetes, FARXIGA® (dapagliflozin) 5 mg & 10 mg tablets
Diabetes Canada Clinical Practice Guidelines
Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3 CKD – AJKD Blog
Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose- lowering efficacy: cohort study using trial and routine clinical data
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update - ScienceDirect
Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. - Abstract - Europe PMC
Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP
Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists – touchENDOCRINOLOGY
Type 2 Diabetes, FARXIGA® (dapagliflozin) 5 mg & 10 mg tablets
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update - ScienceDirect
Ozempic® vs. Trulicity®: SUSTAIN 7 Clinical Trial Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg
Survey to Specify SGLT2 Inhibitor Choice in T2DM Management, Ghosal
